TG Therapeutics, Inc.
General ticker "TGTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $5.1B (TTM average)
TG Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -23.9%.
Estimated limits based on current volatility of 2.4%: low 28.26$, high 29.66$
Factors to consider:
- Total employees count: 338 as of 2024
- US accounted for 94.2% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Regulatory and compliance, Clinical trial success, Labor/talent shortage/retention, Intellectual property risks, Expansion risks
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [25.19$, 55.13$]
- 2025-12-31 to 2026-12-31 estimated range: [23.60$, 51.35$]
Financial Metrics affecting the TGTX estimates:
- Positive: with PPE of 228.4 at the end of fiscal year the price was neutral
- Negative: Operating cash flow per share per price, % of -0.87 <= 0.01
- Positive: 7.67 < Operating profit margin, % of 12.74
- Positive: 19.40 < Shareholder equity ratio, % of 38.49 <= 42.68
- Positive: Investing cash flow per share per price, % of -0.02 > -0.63
- Positive: 1.87 < Return on assets ratio (scaled to [-100,100]) of 3.89
- Negative: negative Industry operating income (median)
- Negative: Inventory ratio change, % of 8.62 > 0.80
- Positive: Interest expense per share per price, % of 0.52 <= 0.73
Short-term TGTX quotes
Long-term TGTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $233.66MM | $329.00MM | $0.00MM |
| Operating Expenses | $213.03MM | $287.07MM | $0.00MM |
| Operating Income | $20.63MM | $41.93MM | $0.00MM |
| Non-Operating Income | $-7.57MM | $-16.34MM | $447.18MM |
| Interest Expense | $12.62MM | $24.03MM | $0.00MM |
| R&D Expense | $76.19MM | $94.29MM | $0.00MM |
| Income(Loss) | $13.06MM | $25.59MM | $447.18MM |
| Taxes | $0.39MM | $2.21MM | $0.00MM |
| Profit(Loss)* | $12.67MM | $23.38MM | $447.18MM |
| Stockholders Equity | $160.50MM | $222.36MM | $648.02MM |
| Inventory | $39.82MM | $110.46MM | $125.59MM |
| Assets | $329.59MM | $577.69MM | $1,063.25MM |
| Operating Cash Flow | $-31.41MM | $-40.52MM | $-24.77MM |
| Capital expenditure | $0.00MM | $0.04MM | $0.21MM |
| Investing Cash Flow | $-50.65MM | $-1.04MM | $13.80MM |
| Financing Cash Flow | $72.70MM | $128.53MM | $-89.73MM |
| Earnings Per Share** | $0.09 | $0.16 | $3.10 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.